LearnGlossaryMarketStocksSuperinvestorsSign in

OTLK

Outlook Therapeutics, Inc.

Healthcare · $116M market cap

Verdict

We can't put a fair value on OTLK right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth2.8% a year✗
Sales growth-12.2% a year✗
Free cash flow growth—?
Return on invested capital—?

Follow OTLK

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Lundquist Kevin Michael

Chief Financial Officer · 2026-09-01

Award

$315K

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works